Insmed, Inc. (NASDAQ:INSM) Shares Sold by Yorktown Management & Research Co Inc

Yorktown Management & Research Co Inc reduced its holdings in Insmed, Inc. (NASDAQ:INSM - Free Report) by 46.7% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,850 shares of the biopharmaceutical company's stock after selling 5,120 shares during the period. Yorktown Management & Research Co Inc's holdings in Insmed were worth $446,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Oppenheimer Asset Management Inc. grew its holdings in shares of Insmed by 37.7% in the first quarter. Oppenheimer Asset Management Inc. now owns 19,935 shares of the biopharmaceutical company's stock valued at $1,521,000 after purchasing an additional 5,453 shares during the period. Whalen Wealth Management Inc. purchased a new stake in shares of Insmed in the 1st quarter valued at approximately $217,000. Avior Wealth Management LLC increased its holdings in shares of Insmed by 82.2% during the 1st quarter. Avior Wealth Management LLC now owns 4,151 shares of the biopharmaceutical company's stock worth $317,000 after buying an additional 1,873 shares during the last quarter. Sowell Financial Services LLC acquired a new stake in shares of Insmed during the 1st quarter worth approximately $255,000. Finally, Wealth Enhancement Advisory Services LLC raised its position in shares of Insmed by 16.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 3,772 shares of the biopharmaceutical company's stock valued at $288,000 after buying an additional 541 shares during the period.

Analyst Upgrades and Downgrades

Several equities analysts have recently commented on the company. Royal Bank Of Canada upped their price target on Insmed from $99.00 to $106.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. UBS Group lowered their target price on shares of Insmed from $110.00 to $109.00 and set a "buy" rating for the company in a research note on Friday, May 9th. Jefferies Financial Group reiterated a "buy" rating on shares of Insmed in a research report on Tuesday, June 10th. HC Wainwright upped their price objective on shares of Insmed from $90.00 to $120.00 and gave the stock a "buy" rating in a report on Wednesday, June 11th. Finally, Leerink Partners increased their price objective on shares of Insmed from $100.00 to $115.00 and gave the stock an "outperform" rating in a research report on Tuesday, June 10th. One equities research analyst has rated the stock with a sell rating and seventeen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $106.80.

Insmed Stock Down 1.0%

NASDAQ INSM traded down $1.05 during trading hours on Wednesday, hitting $104.85. 3,523,867 shares of the company were exchanged, compared to its average volume of 2,179,750. The company has a quick ratio of 5.44, a current ratio of 5.86 and a debt-to-equity ratio of 11.38. The firm has a market cap of $19.89 billion, a price-to-earnings ratio of -17.62 and a beta of 0.80. The company has a 50 day moving average of $76.19 and a two-hundred day moving average of $74.95. Insmed, Inc. has a 52-week low of $60.40 and a 52-week high of $106.84.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($1.42) earnings per share for the quarter, missing the consensus estimate of ($1.36) by ($0.06). Insmed had a negative net margin of 265.93% and a negative return on equity of 446.98%. The firm had revenue of $92.82 million during the quarter, compared to analyst estimates of $91.63 million. During the same period last year, the business earned ($1.06) EPS. The firm's revenue was up 22.9% compared to the same quarter last year. Equities research analysts anticipate that Insmed, Inc. will post -4.56 earnings per share for the current year.

Insider Transactions at Insmed

In related news, CEO William Lewis sold 129,805 shares of the business's stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $100.39, for a total transaction of $13,031,123.95. Following the completion of the sale, the chief executive officer now owns 233,924 shares in the company, valued at $23,483,630.36. The trade was a 35.69% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Clarissa Desjardins purchased 1,895 shares of the company's stock in a transaction on Tuesday, May 20th. The stock was bought at an average price of $66.87 per share, for a total transaction of $126,718.65. Following the completion of the purchase, the director now directly owns 1,895 shares of the company's stock, valued at $126,718.65. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 488,752 shares of company stock valued at $43,199,826. Insiders own 3.00% of the company's stock.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.